Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

The Proba-3 mission, consisting of two spacecraft that fly in close formation to study the sun, has returned images of the first ever artificial solar eclipse ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The FDA has approved fam-trastuzumab deruxtecan, marketed under the brand name Enhertu, as a new treatment for certain types of advanced breast cancer that have spread or cannot be removed with ...

Learn how TA Instruments' RS-DSC enables rapid thermal stability screening of monoclonal antibody drug products.

Trastuzumab deruxtecan (Enhertu, T-DXd) therapy produced "substantial and durable" overall and intracranial clinical activity in patients with HER2-positive advanced breast cancer, according to ...

Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.